Keyword: Boehringer Ingelheim
AstraZeneca has halted its phase 3 Farxiga trial in chronic kidney disease––a move that could soon spell an FDA approval in the major market.
After nearly five years Xellia Pharmaceuticals has started commercial production at former Boehringer Ingelheim sterile injectables plant.
Boehringer and Lilly's Jardiance is locked in a Type 2 diabetes battle against its SGLT2 rivals, and a leg up in Type 1 now doesn't appear likely.
Aiming to keep pace with its SGLT2 rivals in kidney disease, Lilly and Boehringer's Jardiance scored a speedy FDA review in the indication.
With Boehringer Ingelheim aiming wide in its clinical program for pulmonary fibrosis med Ofev, a new FDA nod should validate its quest.
Multinational drugmakers are restricting travel and limiting gatherings—and requiring vendors to do the same—as COVID-19 breaks out worldwide.
Three Biogen employees have tested positive for COVID-19 following a management meeting in Boston.
Several Big Pharma companies have either prohibited travel to and from China or postponed business meetings in affected areas.
An SGLT2 arms race is currently underway for heart failure patients, and not without reason: the market will likely continue to boom this decade.
Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.